CD180 Overexpression in Follicular Lymphoma

CD180 Overexpression in Follicular Lymphoma Is Restricted to the Lymph Node Compartment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02978898

Enrollment

184

Registered

2016-12-01

Start date

2012-06-30

Completion date

2015-06-30

Last updated

2016-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Follicular Lymphoma

Keywords

Follicular Lymphoma, flow cytometry, CD180, Toll-like receptor, lymphoproliferative disease

Brief summary

Background:Altered Toll-like receptor (TLR) expression levels and/or mutations in its signaling pathway (such as MyD88 mutation) contribute to the pathogenesis of lymphoproliferative disorders (LPD). CD180 is an orphan member of the TLR family that modulates the signaling of several TLRs, but only limited studies have evaluated its expression by flow cytometry (FCM) in LPD. Methods: Using a multiparameter FCM approach, biologists have assessed CD180 mean fluorescence intensity (MFI) in lymph nodes (LNs) and peripheral blood (PB) samples obtained from patients with follicular lymphoma (FL; LN/PB, n=44/n=15), chronic lymphocytic leukemia (CLL, n=26/n=21), mantle cell lymphoma (MCL, n=13/n=17), and marginal zone lymphoma (MZL, n=16/n=12). Specimens from non-tumoral PB and LN (n=8/n=12) were used as controls.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Samples from patients with: * LF: Follicular lymphoma * MCL: Mantle cell lymphoma * CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia * MZL : splenic marginal zone * Clt :control B-cells

Exclusion criteria

* Patient \<18 years old

Design outcomes

Primary

Measure	Time frame	Description
Immunophenotype Analysis by Flow Cytometry of lymph nodes samples at inclusion	At inclusion, day 0.	Using a multiparameter FCM approach, biologists assessed the CD180 expression by our routine antigen panel in LN suspensions as well as in PB samples. Samples were analyzed on a BD FACSCanto II cytometer (BD FACS DIVA software; Becton Dickinson, San Jose, CA).
Immunophenotype Analysis by Flow Cytometry of peripheral blood samples at inclusion	At inclusion, day 0.	Using a multiparameter FCM approach, biologists assessed the CD180 expression by our routine antigen panel in LN suspensions as well as in PB samples. Samples were analyzed on a BD FACSCanto II cytometer (BD FACS DIVA software; Becton Dickinson, San Jose, CA).

Outcome results